二水合盐酸纳洛酮结构式
|
常用名 | 二水合盐酸纳洛酮 | 英文名 | Naloxone hydrochloride dihydrate |
---|---|---|---|---|
CAS号 | 51481-60-8 | 分子量 | 399.866 | |
密度 | N/A | 沸点 | N/A | |
分子式 | C19H26ClNO6 | 熔点 | 182 °C (dec.)(lit.) | |
MSDS | 中文版 美版 | 闪点 | 288.4ºC | |
符号 |
GHS07 |
信号词 | Warning |
二水合盐酸纳洛酮用途Naloxone HCl Dihydrate is an opioid inverse agonist drug used to counter the effects of opiate overdose. |
中文名 | 二水合盐酸纳洛酮 |
---|---|
英文名 | Naloxone hydrochloride dihydrate |
中文别名 | 17-烯丙基-4,5a-环氧基-3,14-二羟基吗啡喃-6-酮盐酸盐二水合物 | 盐酸纳洛酮二水合物 |
英文别名 | 更多 |
熔点 | 182 °C (dec.)(lit.) |
---|---|
分子式 | C19H26ClNO6 |
分子量 | 399.866 |
闪点 | 288.4ºC |
精确质量 | 399.144867 |
PSA | 88.46000 |
LogP | 1.91270 |
外观性状 | 白色至灰白色粉末 |
储存条件 | 密闭于2-8 ºC阴凉干燥环境中 |
稳定性 | 遵照规定使用和储存则不会分解。 |
水溶解性 | ethanol: 3.3 mg/mL stable for several months refrigerated if protected from light. |
分子结构 | 1、摩尔折射率:无可用 2、 摩尔体积(cm3/mol):无可用 3、 等张比容(90.2K):无可用 4、 表面张力(dyne/cm):无可用 5、 极化率:无可用 |
计算化学 | 1.疏水参数计算参考值(XlogP):无 2.氢键供体数量:5 3.氢键受体数量:7 4.可旋转化学键数量:2 5.互变异构体数量:6 6.拓扑分子极性表面积72 7.重原子数量:27 8.表面电荷:0 9.复杂度:594 10.同位素原子数量:0 11.确定原子立构中心数量:4 12.不确定原子立构中心数量:0 13.确定化学键立构中心数量:0 14.不确定化学键立构中心数量:0 15.共价键单元数量:4 |
更多 | 1. 性状:白色粉末 2. 密度(g/mL,25/4℃):无可用 3. 相对蒸汽密度(g/mL,空气=1):无可用 4. 熔点(ºC):182 5. 沸点(ºC,常压):无可用 6. 沸点(ºC,5.2kPa):无可用 7. 折射率:无可用 8. 闪点(ºC):无可用 9. 比旋光度(º):无可用 10. 自燃点或引燃温度(ºC):无可用 11. 蒸气压(kPa,25ºC):无可用 12. 饱和蒸气压(kPa,60ºC):无可用 13. 燃烧热(KJ/mol):无可用 14. 临界温度(ºC):无可用 15. 临界压力(KPa):无可用 16. 油水(辛醇/水)分配系数的对数值:无可用 17. 爆炸上限(%,V/V):无可用 18. 爆炸下限(%,V/V):无可用 19. 溶解性:无可用 |
符号 |
GHS07 |
---|---|
信号词 | Warning |
危害声明 | H315-H319-H335 |
警示性声明 | P261-P305 + P351 + P338 |
个人防护装备 | dust mask type N95 (US);Eyeshields;Gloves |
危害码 (欧洲) | Xi: Irritant; |
风险声明 (欧洲) | R36/37/38 |
安全声明 (欧洲) | S22-S24/25-S26-S36/37/39 |
危险品运输编码 | NONH for all modes of transport |
WGK德国 | 3 |
Sympathetic activity induced by naloxone-precipitated morphine withdrawal is blocked in genetically engineered mice lacking functional CRF1 receptor.
Toxicol. Appl. Pharmacol. 283(1) , 42-9, (2015) There is large body evidence indicating that stress can lead to cardiovascular disease. However, the exact brain areas and the mechanisms involved remain to be revealed. Here, we performed a series of... |
|
Relationship between noradrenaline release in the locus coeruleus and antiallodynic efficacy of analgesics in rats with painful diabetic neuropathy.
Life Sci. 92(23) , 1138-44, (2013) In animal models of neuropathic pain, the noradrenergic descending pain inhibitory pathways from the locus coeruleus (LC) may be suppressed. However, no study has investigated the correlation between ... |
|
Effects of tramadol on substantia gelatinosa neurons in the rat spinal cord: an in vivo patch-clamp analysis.
PLoS ONE 10 , e0125147, (2015) Tramadol is thought to modulate synaptic transmissions in the spinal dorsal horn mainly by activating µ-opioid receptors and by inhibiting the reuptake of monoamines in the CNS. However, the precise m... |
(4R,4aS,7aR,12bS)-4a,9-dihydroxy-3-prop-2-enyl-2,4,5,6,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinoline-7-one,dihydrate,hydrochloride |
(5α)-17-Allyl-3,14-dihydroxy-4,5-epoxymorphinan-6-one hydrochloride dihydrate |
Morphinan-6-one, 4,5-epoxy-3,14-dihydroxy-17-(2-propen-1-yl)-, (5α)-, hydrochloride, hydrate (1:1:2) |
EINECS 206-611-0 |
MFCD00150901 |
Naloxone HCl Dihydrate |
Naloxone hydrochloride dihydrate |